Affordable Access

Access to the full text

Immunomodulatory Strategies Targeting Dendritic Cells to Improve Corneal Graft Survival

Authors
  • Schönberg, Alfrun1
  • Hamdorf, Matthias1
  • Bock, Felix1, 2
  • 1 (M.H.)
  • 2 Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50937 Cologne, Germany
Type
Published Article
Journal
Journal of Clinical Medicine
Publisher
MDPI AG
Publication Date
Apr 28, 2020
Volume
9
Issue
5
Identifiers
DOI: 10.3390/jcm9051280
PMID: 32354200
PMCID: PMC7287922
Source
PubMed Central
Keywords
License
Green

Abstract

Even though the cornea is regarded as an immune-privileged tissue, transplantation always comes with the risk of rejection due to mismatches between donor and recipient. It is common sense that an alternative to corticosteroids as the current gold standard for treatment of corneal transplantation is needed. Since blood and lymphatic vessels have been identified as a severe risk factor for corneal allograft survival, much research has focused on vessel regression or inhibition of hem- and lymphangiogenesis in general. However, lymphatic vessels have been identified as required for the inflammation’s resolution. Therefore, targeting other players of corneal engraftment could reveal new therapeutic strategies. The establishment of a tolerogenic microenvironment at the graft site would leave the recipient with the ability to manage pathogenic conditions independent from transplantation. Dendritic cells (DCs) as the central player of the immune system represent a target that allows the induction of tolerogenic mechanisms by many different strategies. These strategies are reviewed in this article with regard to their success in corneal transplantation.

Report this publication

Statistics

Seen <100 times